Inhibition of LDL oxidation by a new estradiol receptor modulator compound LY-139478, comparative effect with other steroids.
Oxidation of low-density lipoprotein (LDL) is postulated to be essential for the development of atherosclerosis. LY-139478 is a new non-steroidal potent estrogen analog, but its effects on in vitro LDL oxidation have not been completely elucidated. We investigated the ability of LY-139478 to inhibit in vitro copper sulfate-mediated LDL oxidation using several methods, including conjugated diene (CD) accumulation, relative electrophoretic mobility on agarose gel, thiobarbituric acid-reactive substances (TBARS) assay, and superoxide anions scavenging activity. The antioxidative potential of LY-139478 was compared to testosterone (T), 17-alpha-estradiol (17alphaE), 17-beta-estradiol (17betaE), dehydroepiandrosterone (D), and dehydroepiandrosterone-3-sulfate (DS). LY-139478 was superior to 17alphaE and 17betaE in prolonging the lag phase and decreasing the slope and peak concentration of the conjugated diene accumulation, decreasing the rate of migration of LDL on agarose gel electrophoresis, and inhibiting the production of melonyldialdehyde (MDA) in the TBARS assay. T, D and DS were ineffective in all three assays. It was previously shown that when native LDL is oxidized by previously oxidized LDL (secondary oxidation) the lag phase is lost (Schnitzer et al. Free Rad Res 1995;23:137). LY-139478 was at least 15-fold more effective than 17alphaE, and 17betaE in slowing the propagation phase and reducing CD accumulation in this secondary oxidation, with 50% inhibition at 10 microM and 98% inhibition at 100 microM. However, none restored the lag phase. T, D and DS were ineffective. Superoxide anion generation was inhibited only by DS at high doses (500 microM). These results demonstrate that LY-139478 is an effective inhibitor of LDL oxidation and is superior to natural steroidal hormones, including 17betaE, in protecting against primary and secondary LDL oxidation.
Rattan
A K
AK
Department of Preventive Cardiology, St. Francis Hospital, Roslyn, NY 11576-1348, USA.
Arad
Y
Y
D000975:Antioxidants / Q000494:pharmacology; D019327:Copper Sulfate / Q000494:pharmacology; D003687:Dehydroepiandrosterone / Q000494:pharmacology; D019314:Dehydroepiandrosterone Sulfate / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004587:Electrophoresis, Agar Gel; D004958:Estradiol / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000494:pharmacology*; D012739:Gonadal Steroid Hormones / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008315:Malondialdehyde / Q000378:metabolism; D010084:Oxidation-Reduction; D011759:Pyrrolidines / Q000494:pharmacology*; D013481:Superoxides / Q000378:metabolism; D013739:Testosterone / Q000494:pharmacology; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D013876:Thiophenes / Q000494:pharmacology*
D000975:Antioxidants; D004965:Estrogen Antagonists; D012739:Gonadal Steroid Hormones; D008077:Lipoproteins, LDL; D011759:Pyrrolidines; D017392:Thiobarbituric Acid Reactive Substances; D013876:Thiophenes; D013481:Superoxides; D013739:Testosterone; D003687:Dehydroepiandrosterone; D004958:Estradiol; D008315:Malondialdehyde; D019314:Dehydroepiandrosterone Sulfate; C025430:LY 117018; D019327:Copper Sulfate